CClinicalTrials.gg
RecruitingNCT04913467Vita-GrAIDUpdated Feb 14, 2023

Effect of Ileocolonic Delivered Vitamins and an Anti-Inflammatory Diet on Crohn's Disease and Healthy Volunteers

An interventional study of Groningen Anti-Inflammatory Diet (GrAID) and ColoVit capsule in Crohn Disease, sponsored by University Medical Center Groningen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-14.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2021; still recruiting 4 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study will evaluate if the Groningen Anti-Inflammatory Diet and the ileocolonic delivery of vitamin B2, B3 and C can positively influence the course of Crohn's disease and can positively alter the gut microbiome of Crohn's disease patients as well as healthy volunteers.

Read the detailed description

It is becoming increasingly more well known that diet and the microbiome have a pivotal role in the development and course of inflammatory bowel diseases (IBD). Strict exclusive enteral nutrition (EEN) can induce remission in Crohn's Disease (CD) and is the standard treatment in paediatric CD. Implementing a restrictive diet in adults is difficult; adult patients do not tend to adhere to EEN. Recently, the CD-exclusion diet (CDED) combined with partial enteral nutrition demonstrated to be effective in CD-patients with flares.

Additionally, accumulating evidence suggests that intake of vitamins can influence disease course, mainly by beneficially modulating the gut microbiota and gut redox potential, especially if the vitamins can be delivered to the colon.

Nevertheless, no dietary guidelines are available to physicians and patients. Due to complaints of certain foods and patients' eagerness to postpone new flares, patients start experimenting with their food. As patients with CD are already often malnourished, this poorly substantiated experimenting puts them even more at risk for malnutrition and could have a potential negative effect on their disease outcomes. Next, quality of life of patients decreases and healthcare costs will rise. Therefore, both patients and physicians are in desperate need of evidence for an anti-inflammatory dietary advice in CD. As compliance to a diet increases when they are supported by family members, their household members will also be asked to participate in the study. Simultaneously studying their healthy family members will also provide information of the effect of this anti-inflammatory diet or intake of lieocolonic-delivered vitamins on their microbiome and markers of inflammation and oxidative stress.

02

Conditions studied

  • Crohn Disease

Browse trials for

Keywords

  • Inflammatory Bowel Disease
  • IBD
  • Crohn
  • Vitamins
  • Diet
  • Riboflavin
  • Ascorbic Acid
  • Niacin
  • Microbiome
03

In context

Crohn Disease

1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.

This study's planned enrollment of 510 is above the median of 66 across 1,188 interventional studies indexed under Crohn Disease.

Browse Crohn Disease studies →

Lead sponsor

University Medical Center Groningen is the lead sponsor of 609 studies on the registry; 174 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria CD patients:

  • Participant understands the study procedures and signed an informed consent to participate in this study
  • Previously diagnosed with CD; Montreal classification: L1 (Ileal), L2 (colonic), or L3 (ileocolonic).
  • Low-mild disease activity (no clinically relevant symptoms and HBI\<8 or CDAI \<220)
  • Evidence of mucosal inflammation (faecal calprotectin ≥100 μg/g)
  • Able to attend to the outpatient clinic of the UMCG, Martini Hospital, MCL Leeuwarden or Isala
  • ≥18 years of age
  • Able to use oral feeding and willing to undergo a dietary intervention (Follow a diet or use a vitamin B2/B3/C supplement or placebo)

Inclusion Criteria healthy volunteers:

  • Participant understands the study procedures and signed an informed consent to participate in this study
  • Never been diagnosed with IBD or any other chronic inflammatory condition.
  • Participant has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the investigator on the basis of medical history and routine laboratory test results.
  • Able to attend to the outpatient clinic of the UMCG, Martini Hospital, MCL Leeuwarden or Isala
  • ≥18 year of age
  • Able to use oral feeding and willing to undergo a dietary intervention (Follow a diet or use a vitamin B2/B3/C supplement or placebo)

Exclusion Criteria CD patients:

  • Life expectancy \<12 months
  • Active Crohn's disease (HBI≥8 or CDAI>220), or expecting drug intervention within 3 months
  • Colonoscopy and colon cleansing in the past 3 months;
  • Use antibiotics, probiotics (eg Yakult, Vifit, Activia) or specific prebiotics supplements 3 weeks prior to the start of the intervention
  • Use of vitamin/mineral supplements 1 week prior to the start of the intervention (except for vitamin D and/or calcium)
  • Use Methotrexate drugs or chronic use of antacids, H2 or proton-pump inhibitors
  • With a history of GI disorders or GI surgery that are likely to interfere with the pH-dependent mode of action of the Colovit-capsule
  • Patients with a pouch or stoma
  • Pregnant or breastfeeding (or foreseen pregnancy during dietary intervention period)
  • Swallowing disorders, not able to tolerate oral food, or use of tube feeding (EEN)
  • Previously proven anaphylactic reaction to foods included in the food boxes
  • Previously diagnosed with Celiac Disease or following a gluten-free diet
  • Following a vegetarian or vegan diet

Exclusion Criteria healthy subjects:

  • Life expectancy \<12 months
  • Previously diagnosed with IBD or any other chronic inflammatory condition
  • Colonoscopy and colon cleansing in the past 3 months;
  • Use antibiotics, probiotics (eg Yakult, Vifit, Activia) or specific prebiotics supplements 3 weeks prior to the start of the intervention
  • Use of vitamin/mineral supplements 1 week prior to the start of the intervention (except for vitamin D and/or calcium)
  • With a history of GI disorders or taken drugs that are likely to interfere with mode of action of interventions, such as chronic use of antacids or proton-pump inhibitors
  • Abnormal clinical chemistry and haematology laboratory test results of clinical significance that in the judgment of the investigator would interfere with the participant's ability to comply with the study protocol (which might confound the interpretation of the study results), or put the participant at undue risk.
  • Presence of a stoma
  • History or presence of cancer in the prior two years, except for non-melanoma skin cancer.
  • Recent history of (within 12 months of screening visit) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as >60g (men) / 40g (women) pure alcohol per day (1.5 l / 1 l beer resp. 0.75 l / 0.5 l wine).
  • Pregnant or breastfeeding (or foreseen pregnancy during dietary intervention period) The method of contraception must be recorded in the source documentation.
  • Swallowing disorders, not able to tolerate oral food, or use of tube feeding (EEN)
  • Previously proven anaphylactic reaction to foods included in the food boxes
  • Previously diagnosed with Celiac Disease or following a gluten-free diet
  • Following a vegetarian or vegan diet
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
510 participants (estimated)

Study arms

  • Experimental
    Groningen Anti-Inflammatory Diet (GrAID)

    Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups.

    Other: Groningen Anti-Inflammatory Diet (GrAID)

  • Experimental
    ColoVit capsule

    2 times daily intake of a supplement containing 37,5 mg vitamin B2, 2,5 mg vitamin B3 and 250 mg vitamin C in a ColoPulse-coated capsule, a pH-sensitive coating allowing ileocolonic-targeted-delivery

    Dietary Supplement: ColoVit capsule

  • Placebo comparator
    Placebo capsule

    2 times daily intake of a capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit

    Other: ColoPulse-placebo capsule

Interventions

  • OtherGroningen Anti-Inflammatory Diet (GrAID)

    Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups. Basically, subjects will be instructed to increase uptake of food components that hold potential anti-inflammatory proportions and to avoid food components that may showcase potential pro-inflammatory proportions.

  • Dietary supplementColoVit capsule

    Vitamin B2/B3/C supplement in a ColoPulse-coated capsule

  • OtherColoPulse-placebo capsule

    A capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit

06

What researchers measure

Primary outcomes

  1. Change in faecal calprotectin

    Primary outcome for CD patients

    Time frame: Faeces sample collection at 4 time points: At baseline (0 months), after 3 months, after 6 months, after 12 months

  2. Change in microbiome composition measured by metagenomic sequencing- based profiles

    Primary outcome for healthy volunteers and CD patients

    Time frame: Faeces sample collection at 3 time points: At baseline (0 months), after 3 months, after 12 months

Secondary outcomes

  1. The number of flares (defined as faecal calprotectin >200 μg/g and Crohn's Disease Activity Index (CDAI) ≥220 points)

    Secondary outcome for CD patients

    Time frame: Faeces sample collection and CDAI score determination at 4 time points: At baseline (0 months), after 3 months, after 6 months, after 12 months

  2. Improvements of Quality of life scores as assessed by Inflammatory Bowel Disease Questionnaire (Score range of 32-224, The higher the score the higher the Quality of Life)

    Secondary outcome for CD patients

    Time frame: Questionnaires at 3 time points: At baseline (0 months), after 3 months, after 12 months

  3. Improvements of Quality of life scores as assessed Food Related Quality of Life Questionnaire (Score range of 29-145, The higher the score the higher the Food related-Quality of Life)

    Secondary outcome for CD patients and healthy volunteers

    Time frame: Questionnaires at 3 time points: At baseline (0 months), after 3 months, after 12 months

  4. Adherence to the dietary interventions as assessed by a Dietary Compliance Questionnaire

    Secondary outcome for CD patients and healthy volunteers

    Time frame: Questionnaires at 3 time points: At baseline (0 months), after 3 months, after 12 months

07

Study locations

1 of 1 sites recruiting
  • University Medical Center Groningen
    Groningen, 9713GZ, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — There is no plan to make individual participant data available to other researchers outside of the study team.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04913467
Lead sponsor
University Medical Center Groningen
Responsible party
Prof. dr. G. Dijkstra (Clinical Professor, Head of Inflammatory Bowel Disease Center and Intestinal Transplantation Center, University Medical Center Groningen) — Principal investigator
First posted
Jun 4, 2021
Start date
Oct 8, 2021
Primary completion
Jul 1, 2024 (estimated)
Completion
Jul 1, 2025 (estimated)
Last update
Feb 14, 2023

Study contacts

Gerard Dijkstra, MD PhD
Contact
gerard.dijkstra@umcg.nl
+31 050 3612620

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion